ID
37674
Descrizione
Study ID: 111592 Clinical Study ID: 111592 Study Title: A Randomized, Double-blind, Placebo-controlled, Doseescalation Study to Assess the Anti-inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996840 See https://clinicaltrials.gov/ct2/show/NCT00996840 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Placebo, SB-681323 Trade Name: N/A Study Indication: Lung Injury, Acute The primary objective of this phase 2 trial is to evaluate the safety and tolerability of intravenous dilmapimod/SB-681323 given in escalating dosages and over different intervals for three days in trauma patients at risk for the development of ALI or ARDS. This study consists of Screening, infusion of dilmapimod/SB-681323 on days 1-3, examination/sampling up to early day 5 (denoted as "Day 3 - 48 hrs") and a Follow-up on day 7. There are four cohorts, cohorts 1 and 3 receive the medication (or placebo) infusion over 4 hours, cohorts 2 and 4 over 24 hours. This form is to be filled with data regarding pharmacodynamic results relating to the coagulation system and lung epithelial cell injury, taken repeatedly on Day 1 and 3, and can also be used for repeat analyses.
collegamento
https://clinicaltrials.gov/ct2/show/NCT00996840
Keywords
versioni (2)
- 13/08/19 13/08/19 -
- 15/08/19 15/08/19 - Sarah Riepenhausen
Titolare del copyright
GlaxoSmithKline
Caricato su
15 agosto 2019
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
SB-681323 in ALI/ARDS risk patients - NCT00996840
Pharmacodynamics Results
- StudyEvent: ODM
Similar models
Pharmacodynamics Results
- StudyEvent: ODM
C1254595 (UMLS CUI-2)
C0304229 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C1264639 (UMLS CUI [1,2])
C0031328 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C0525032 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0525032 (UMLS CUI [1,3])
C0332307 (UMLS CUI [1,2])
C0491338 (UMLS CUI [1,3])
C0491338 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0491338 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C0030605 (UMLS CUI [1,2])
C2350015 (UMLS CUI [1,2])
C0030605 (UMLS CUI [1,3])